Daniel O'Reilly
Affiliations: | RNA Therapeutics Institute, University of Massachusetts Medical School |
Area:
oligonucleotide synthesis, chemical modification and translational biologyGoogle:
"Daniel O'Reilly"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Masad J. Damha | grad student | 2014-2019 | McGill |
| Anastasia Khvorova | post-doc | 2020- | University of Massachusetts Medical School, USA (Neurotree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sapp E, Boudi A, Iwanowicz A, et al. (2025) Detection of HTTex1p by western blot and immunostaining of HD human and mouse brain using neo-epitope antibody P90 highlights impact of CAG repeat expansion on its size, solubility, and response to MSH3 silencing. Biorxiv : the Preprint Server For Biology |
| Barber HM, Pater AA, Gagnon KT, et al. (2024) Chemical engineering of CRISPR-Cas systems for therapeutic application. Nature Reviews. Drug Discovery |
| Mathews EW, Coffey SR, Gärtner A, et al. (2024) Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding. Biorxiv : the Preprint Server For Biology |
| Rivera Flores IV, Monopoli K, Jackson S, et al. (2024) Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy. Nucleic Acid Therapeutics |
| Allen S, O'Reilly D, Miller R, et al. (2024) mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs . Nucleic Acid Therapeutics |
| Allen S, O'Reilly D, Miller R, et al. (2024) mRNA nuclear clustering leads to a difference in mutant huntingtin mRNA and protein silencing by siRNAs . Biorxiv : the Preprint Server For Biology |
| Engelbeen S, O'Reilly D, Van De Vijver D, et al. (2023) Challenges of Assessing Exon 53 Skipping of the Human Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy. Nucleic Acid Therapeutics. 33: 348-360 |
| O'Reilly D, Belgrad J, Ferguson C, et al. (2023) Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| O'Reilly D, Belgrad J, Ferguson C, et al. (2023) Di-valent siRNA Mediated Silencing of MSH3 Blocks Somatic Repeat Expansion in Mouse Models of Huntington's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy |
| Hariharan VN, Shin M, Chang CW, et al. (2023) Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America. 120: e2219523120 |